Tolerability & Patient Satisfaction

ZYRTEC® provides generally well–tolerated symptom relief that satisfies patients’ needs

  • Discontinuation due to adverse events in clinical trials was not significantly different between ZYRTEC® and placebo (2.9% vs 2.4%, respectively)1
  • In clinical trials, 14% of patients taking ZYRTEC® 10 mg reported somnolence (n=2034) vs 6% for placebo (n=1612)1
  • In clinical trials, 1% of patients discontinued due to somnolence1
  • 93% of patients reported satisfaction with prescription ZYRTEC® in a survey of more than 180,000 respondents*1

Children’s ZYRTEC® delivers patient satisfaction

  • In trials with more than 200 pediatric patients, of those who reported somnolence (4.2%), 100% stayed with ZYRTEC® during the trial†1

*Based on a consumer satisfaction telephone survey of 180,643 patients who took prescription ZYRTEC® between 1999 and 2002.

†In trials for US approval with more than 200 patients ages 6 to 11.

References:
1. Data on file, McNEIL-PPC, Inc.